Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Treon

Showing results (81-90 of 323) with videos related to

Pageof 33
Sort By:
British Journal of Haematology|December 19, 2014
Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results databaseJorge J Castillo, Adam J Olszewski, Sandra Kanan, et al.
Seminars in Oncology|April 30, 2003
The malignant clone in Waldenstrom's macroglobulinemiaJitra Kriangkum, Brian J Taylor, Michael J Mant, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 8, 2006
Infectious complications associated with alemtuzumab use for lymphoproliferative disordersStanley I Martin, Francisco M Marty, Karen Fiumara, et al.
Blood|February 7, 2004
Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral bloodJitra Kriangkum, Brian J Taylor, Steven P Treon, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 14, 2013
Comparative response assessment by serum immunoglobulin M M-protein and total serum immunoglobulin M after treatment of patients with Waldenström macroglobulinemiaChristina K Tripsas, Christopher J Patterson, Sacha N Uljon, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemiaSteven P Treon, Christina Hanzis, Christina Tripsas, et al.
Seminars in Oncology|April 30, 2003
Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaDonna Weber, Steven P Treon, Christos Emmanouilides, et al.
Clinical Lymphoma|January 8, 2005
Clinical responses to sildenafil in Waldenstrom's macroglobulinemiaSteven P Treon, Olivier Tournilhac, Andrew R Branagan, et al.
British Journal of Haematology|May 8, 2014
Transcriptional repression of plasma cell differentiation is orchestrated by aberrant over-expression of the ETS factor SPIB in Waldenström macroglobulinaemiaYangsheng Zhou, Xia Liu, Lian Xu, et al.
Blood|May 14, 2011
Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumabSteven P Treon, Jacob D Soumerai, Zachary R Hunter, et al.
Pageof 33

Showing results (81-90 of 323) with videos related to

Sort By:
Pageof 33
British Journal of Haematology|December 19, 2014
Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results databaseJorge J Castillo, Adam J Olszewski, Sandra Kanan, et al.
Seminars in Oncology|April 30, 2003
The malignant clone in Waldenstrom's macroglobulinemiaJitra Kriangkum, Brian J Taylor, Michael J Mant, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 8, 2006
Infectious complications associated with alemtuzumab use for lymphoproliferative disordersStanley I Martin, Francisco M Marty, Karen Fiumara, et al.
Blood|February 7, 2004
Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral bloodJitra Kriangkum, Brian J Taylor, Steven P Treon, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 14, 2013
Comparative response assessment by serum immunoglobulin M M-protein and total serum immunoglobulin M after treatment of patients with Waldenström macroglobulinemiaChristina K Tripsas, Christopher J Patterson, Sacha N Uljon, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemiaSteven P Treon, Christina Hanzis, Christina Tripsas, et al.
Seminars in Oncology|April 30, 2003
Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaDonna Weber, Steven P Treon, Christos Emmanouilides, et al.
Clinical Lymphoma|January 8, 2005
Clinical responses to sildenafil in Waldenstrom's macroglobulinemiaSteven P Treon, Olivier Tournilhac, Andrew R Branagan, et al.
British Journal of Haematology|May 8, 2014
Transcriptional repression of plasma cell differentiation is orchestrated by aberrant over-expression of the ETS factor SPIB in Waldenström macroglobulinaemiaYangsheng Zhou, Xia Liu, Lian Xu, et al.
Blood|May 14, 2011
Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumabSteven P Treon, Jacob D Soumerai, Zachary R Hunter, et al.
Pageof 33